410 related articles for article (PubMed ID: 30646152)
1. Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels.
Pandya A; Asch DA; Volpp KG; Sy S; Troxel AB; Zhu J; Weinstein MC; Rosenthal MB; Gaziano TA
JAMA Netw Open; 2018 Sep; 1(5):e182008. PubMed ID: 30646152
[TBL] [Abstract][Full Text] [Related]
2. Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.
Asch DA; Troxel AB; Stewart WF; Sequist TD; Jones JB; Hirsch AG; Hoffer K; Zhu J; Wang W; Hodlofski A; Frasch AB; Weiner MG; Finnerty DD; Rosenthal MB; Gangemi K; Volpp KG
JAMA; 2015 Nov; 314(18):1926-35. PubMed ID: 26547464
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study.
Lee Y; Mozaffarian D; Sy S; Huang Y; Liu J; Wilde PE; Abrahams-Gessel S; Jardim TSV; Gaziano TA; Micha R
PLoS Med; 2019 Mar; 16(3):e1002761. PubMed ID: 30889188
[TBL] [Abstract][Full Text] [Related]
6. Effect of Patient Financial Incentives on Statin Adherence and Lipid Control: A Randomized Clinical Trial.
Barankay I; Reese PP; Putt ME; Russell LB; Loewenstein G; Pagnotti D; Yan J; Zhu J; McGilloway R; Brennan T; Finnerty D; Hoffer K; Chadha S; Volpp KG
JAMA Netw Open; 2020 Oct; 3(10):e2019429. PubMed ID: 33034639
[TBL] [Abstract][Full Text] [Related]
7. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement.
Smith KC; Paltiel AD; Yang HY; Collins JE; Katz JN; Losina E
Osteoarthritis Cartilage; 2018 Nov; 26(11):1495-1505. PubMed ID: 30092263
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a Multicomponent Intervention for Hypertension Control in Low-Income Settings in Argentina.
Zhang Y; Yin L; Mills K; Chen J; He J; Palacios A; Riviere AP; Irazola V; Augustovski F; Shi L
JAMA Netw Open; 2021 Sep; 4(9):e2122559. PubMed ID: 34519769
[TBL] [Abstract][Full Text] [Related]
13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
14. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Davies GM; Vyas A; Baxter CA
J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
[TBL] [Abstract][Full Text] [Related]
17. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults.
Kohli-Lynch CN; Bellows BK; Zhang Y; Spring B; Kazi DS; Pletcher MJ; Vittinghoff E; Allen NB; Moran AE
J Am Coll Cardiol; 2021 Nov; 78(20):1954-1964. PubMed ID: 34763772
[TBL] [Abstract][Full Text] [Related]
20. Are financial incentives cost-effective to support smoking cessation during pregnancy?
Boyd KA; Briggs AH; Bauld L; Sinclair L; Tappin D
Addiction; 2016 Feb; 111(2):360-70. PubMed ID: 26370095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
